Fungal proteins

Fungal proteins represent the diverse array of proteins encoded by the genomes of fungi, including pathogenic species such as Candida, Aspergillus, and Cryptococcus. These proteins are essential for fungal growth, survival, and virulence, making them primary targets for antifungal medications. Key therapeutic targets include enzymes like lanosterol 14-alpha demethylase, which is involved in ergosterol synthesis, and 1,3-beta-glucan synthase, which is critical for cell wall integrity (Source: StatPearls, NBK493171). Because fungi are eukaryotic organisms, many of their proteins share structural similarities with human proteins, which can lead to off-target effects and toxicity (Source: PMC, PMC3708393). Antifungal drugs such as azoles, echinocandins, and allylamines are designed to selectively inhibit these fungal proteins to treat a wide range of infections (Source: PubChem, CID 154900). The study of the fungal proteome is crucial for developing new therapeutic strategies and addressing the rising challenge of antifungal resistance. Specific proteins like squalene epoxidase are also targeted to disrupt the early stages of ergosterol biosynthesis (Source: NCBI, PMID: 10930357).

Other names

Mycological proteinsFungal proteomeFungal polypeptides

Antifungal agents target fungal proteins through various mechanisms: azoles inhibit lanosterol 14-alpha demethylase to prevent ergosterol synthesis; echinocandins non-competitively inhibit 1,3-beta-glucan synthase to disrupt cell wall formation; and allylamines inhibit squalene epoxidase (Source: StatPearls, NBK493171; PubChem, CID 154900).